Suggested Readings

Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management.

Epstein DJ, Dunn J, Deresinski S. Open Forum Infect Dis. 2018;5(8):ofy174.

Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm.

Giovannoni G. Curr Opin Neurol. 2018;31(3):233-243.

Ofatumumab versus teriflunomide in multiple sclerosis.

Hauser SL, Bar-Or A, Cohen JA, et al. N Engl J Med. 2020;383(6):546-557.

Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis.

Hauser SL, Bar-Or A, Comi G, et al. N Engl J Med. 2017;376(3):221-234.

Treatment of multiple sclerosis: a review.

Hauser SL, Cree BAC. Am J Med. 2020;133(12):1380-1390.e2.

The role of infections in multiple sclerosis.

Marrodan M, Alessandro L, Farez MF, Correale J. Mult Scler. 2019;25(7):891-901.

The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: a Delphi consensus statement.

Moiola L, Barcella V, Benatti S, et al. Mult Scler. 2021;27(3):331-346.

Infection mitigation strategies for multiple sclerosis patients on oral and monoclonal disease-modifying therapies.

Smith TE, Kister I. Curr Neurol Neurosci Rep. 2021;21(7):36.

The contribution of enhancing lesions in monitoring multiple sclerosis treatment: is gadolinium always necessary?

Tsantes E, Curti E, Ganazzoli C, et al. J Neurol. 2020;267(9):2642-2647.